Adaptimmune loses $3B biobucks pact with Genentech
Roche’s Genentech has broken off its collaboration and license agreement on off-the-shelf T cell therapies with Adaptimmune.
The pullback means Adaptimmune could miss out on about $3 billion in downstream payments as part of the agreement that was disclosed two and a half years ago. Biobucks, as they’re colloquially called in the industry, are pharma’s approach to drug development pacts and usually don’t come to full fruition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
